TLR7 and glioma: The number of DCs and tumor-reactive T lymphocytes that reached the glioma site was significantly boosted by the topical application of IMQ, as revealed by Xiong et al. Furthermore, as the tumor cells did not produce TLR7 mRNA, soluble IMQ reduced the growth of GL261 cells in a TLR7-independent manner [60,61].